Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate

In the manufacture of sterile ceftriaxone sodium meeting EP 10.5 and USP 43-NF 38 monograph criteria, the (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl thioester (AE-active ester) — the critical acylation partner for 7-aminocephalosporanic acid (7-ACA) — is constructed from Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate through consecutive O-methylation and thioester formation sequences. The initial methylation is charged with a stoichiometric excess of dimethyl sulfate at a verified molar ratio of 1:1.15 (ester to dimethyl sulfate) suspended in anhydrous acetone, maintained under a nitrogen blanket in a glass-lined reactor with an anchor agitator speed of 60–80 rpm. Potassium carbonate is introduced in two portions to maintain pH between 7.5 and 8.2; the dosing rate of dimethyl sulfate is calibrated via a mass flow controller to restrict the internal temperature excursion to a window of −5 °C to +2 °C, as batch records from industrial campaigns have documented that excursions above +5 °C for more than 120 seconds lead to a sharp rise in the (E)-oxime isomer, exceeding the permitted ceiling of ≤ 0.15% for the downstream active pharmaceutical ingredient. After phase separation and vacuum distillation to recover acetone within the ICH Q3C Class 3 residual limit of ≤ 5000 ppm, the resulting (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid (ATMAA) is activated with 2,2′-dibenzothiazyl disulfide (MBTS) in dichloromethane at a precise molar proportion of ATMAA : MBTS : triphenylphosphine = 1 : 0.55 : 1.1 at 18–22 °C over 4–6 hours, forming the AE-active ester which crystallizes upon addition of n-heptane. Terminal application is condensation with 7-ACA in methylene chloride/water biphase to yield ceftriaxone acid, subsequently converted to disodium salt hemipentahydrate sterile powder for injection. The process is executed under ICH Q7 Good Manufacturing Practice, with in-process controls enforcing residual dichloromethane ≤ 600 ppm, residual triphenylphosphine oxide ≤ 0.10%, and heavy metals quantified against ICH Q3D Guideline for Elemental Impurities (Class 1 elements ≤ 0.1 µg/g for As and Pb). The compliance envelope is further delineated in the table below.

What Controls Isomeric Purity During Methylation to Form (Z)-Methoxyimino Intermediate?

When Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate is directed into the cefotaxime sodium supply chain, the critical quality attribute dictating batch release is the (Z)/(E) oxime ether ratio, specifically the absence of the thermodynamically more stable (E)-methoxyimino isomer, which if carried through the downstream sequence becomes an impurity structurally resembling the active moiety yet pharmacologically inactive. On a 5000 L production line equipped with a dimple-jacketed Hastelloy C-22 reactor and a recirculating chiller set to −15 °C, the O-methylation is performed using dimethyl sulfate at a molar charge of 1.13 equivalents relative to the oxime ester, while pulverized anhydrous potassium carbonate (1.45 eq) is titrated in as a slurry in acetone to maintain an apparent pH range of 7.9–8.1 as measured by an in-line pH probe calibrated at low temperature. Reaction calorimetry data from this process indicate an adiabatic temperature rise of 18 °C per mole of dimethyl sulfate hydrolysed, hence the jacket temperature setpoint is held at −10 °C and the feeding period extended to 90–110 minutes to ensure the bulk temperature never exceeds +2 °C; production deviation reports have attributed several lot failures to a cooling water valve malfunction that allowed the batch temperature to spike to +8 °C, resulting in 0.8% (E)-isomer versus the specification limit of ≤ 0.10%. The crude methoxyimino ester is then saponified with 8% w/w aqueous sodium hydroxide at 5–10 °C to yield ATMAA, which is converted to the AE-active ester under analogous conditions to the ceftriaxone route but with an extended dichloromethane wash sequence to remove triphenylphosphine oxide. The final condensation with 7-ACA is performed as a one-pot acylation/hydrolysis in a water/THF solvent system at 0–5 °C. The end product is cefotaxime sodium sterile powder characterized by a specific optical rotation of +58° to +64° (EP 10.5) and a residual solvent profile mandating acetonitrile ≤ 410 ppm and triethylamine ≤ 320 ppm. Compliance is anchored to ICH M7 assessment of mutagenic impurities, particularly the alert for residual dimethyl sulfate (TTC-based limit of 1.5 µg/day intake, translating to a concentration limit of 0.3 ppm in the API assuming a 5 g daily dose), enforced via LC-MS/MS with a limit of quantitation of 0.05 ppm.

Alkylation with tert-Butyl Bromoisobutyrate for Ceftazidime Side-Chain Acid

The ceftazidime pentahydrate (with sodium carbonate or L-arginine for sterile injection) requires a distinctive (Z)-2-(2-aminothiazol-4-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetic acid as the side-chain acid, which is synthesized by O-alkylating Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate with tert-butyl bromoisobutyrate. In a validated manufacturing procedure run in a 3000 L enameled reactor, the oxime ester is dissolved in dimethylformamide (DMF, dried over 4 Å molecular sieves to ≤ 300 ppm water) and reacted with tert-butyl bromoisobutyrate at a molar ratio of 1:1.22 in the presence of cesium carbonate (1.35 eq) as the base, with the slurry agitated at 160 rpm and heated to 55–60 °C for 16–20 hours. The addition rate of the alkyl bromide is controlled to keep the concentration of unreacted alkylating agent below 0.15 mol/L at any point to suppress the formation of quaternary ammonium by-products from the solvent. After aqueous work-up and ethyl acetate extraction, the resulting ethyl ester intermediate is subjected to basic hydrolysis with lithium hydroxide monohydrate (1.05 eq) in a THF/water (4:1 v/v) mixture at 0–5 °C over 3 hours, followed by pH adjustment to obtain the crystalline side-chain acid. Terminal usage is coupling with the 7-aminocephalosporanic acid tert-butyl ester (7-ACA t-butyl ester) via a mixed anhydride process using isobutyl chloroformate and N-methylmorpholine at −15 °C. The resulting protected intermediate is deprotected with trifluoroacetic acid/anisole and crystallized as ceftazidime pentahydrate. The ICH compliance framework for this route extends beyond ICH Q3C to include rigorous control of residual DMF (Class 2, limit ≤ 880 ppm), tert-butanol (Class 3, ≤ 5000 ppm), and 1,4-dioxane (Class 2, ≤ 380 ppm) which is a potential degradation product of THF if peroxides form during storage. Elemental impurity risk assessment per ICH Q3D requires monitoring of palladium (if catalytic hydrogenation is used in the 7-ACA t-butyl ester precursor) and cesium residues (Cs limit typically ≤ 50 µg/g via ICP-MS). The final injectable dosage form is terminally sterilized by gamma irradiation or prepared under aseptic conditions conforming to EU GMP Annex 1.

For cefdinir monohydrate synthesis, the intact (Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetic acid motif is preserved without O-alkylation, necessitating a protection strategy that renders Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate compatible with the downstream acylation of the β-lactam nucleus. On a 2000 L glass-lined reactor train, the starting ester is treated with triphenylchloromethane (TrCl) at a molar ratio of 1:1.05 in dichloromethane in the presence of triethylamine (1.2 eq) at 0–5 °C for 8 h to install the trityl protecting group on the 2-amino group of the thiazole ring, yielding ethyl 2-(2-tritylaminothiazol-4-yl)-2-hydroxyiminoacetate which is isolated by crystallization from methanol. The protected ester is saponified with 1.2 N sodium hydroxide in methanol/water at 25 °C over 4 h to the corresponding carboxylic acid. Activation of this acid is executed via the Vilsmeier reagent formed from phosphorus oxychloride (1.05 eq) and DMF at −10 °C, then condensed with 7-amino-3-vinyl-3-cephem-4-carboxylic acid (7-AVCA) in dichloromethane/THF solvent at −30 to −20 °C, keeping the internal exotherm under −15 °C to avert epimerization at the C-7 position. Deprotection of the trityl group with 98% formic acid at 10–15 °C for 3 h furnishes cefdinir, which is crystallized as the monohydrate from aqueous ethanol. The terminal product is formulated into capsules (300 mg) and oral suspension. Active pharmaceutical ingredient specifications harmonized with JP 18 and USP 43 impose a limit of ≤ 0.50% for the E-isomer of the oxime, ≤ 0.10% for any single unspecified impurity, and residual solvents within the ICH Q3C portfolio: methanol ≤ 3000 ppm, dichloromethane ≤ 600 ppm, formic acid ≤ 500 ppm. The route’s particular heavy metal concern is residual palladium from an earlier 7-AVCA hydrogenolysis step; when palladium-on-carbon is employed, the Pd content in the final API is routinely verified by graphite furnace atomic absorption spectroscopy to be ≤ 5 µg/g, compliant with the oral permitted daily exposure per ICH Q3D.

Veterinary-grade Ceftiofur Hydrochloride: Residual Solvent and Impurity Profiling

Conversion of Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate into the veterinary cephalosporin ceftiofur hydrochloride (sterile suspension for injection in cattle and swine) follows the O-methylation/active ester pathway closely analogous to human ceftriaxone, yet the regulatory baseline shifts to VICH GL18 (Residual Solvents in Veterinary Medicinal Products) and EDQM monographs for veterinary substances, with additional scrutiny on solvents historically used in veterinary intermediate isolation such as chloroform and 1,2-dichloroethane, both of which are banned in this manufacturing chain and replaced with dichloromethane and acetone at controlled levels. The methylation step employs dimethyl sulfate at a molar ratio of 1:1.12 under the same temperature constraints as earlier (−3 to 0 °C), with potassium carbonate charge adjusted to 1.40 eq to compensate for the slightly higher moisture content permitted in the veterinary API stream. The resulting methoxyimino acid is activated to the AE-active ester using MBTS/triphenylphosphine in dichloromethane, but the solvent swap from the crystallization matrix to ethyl acetate prior to condensation with 7-amino-3-[(furan-2-carbonyl)thiomethyl]-3-cephem-4-carboxylic acid (7-ACFT) eliminates heptane as a residual risk; residual ethyl acetate is controlled ≤ 5000 ppm per VICH GL18. The condensation is performed in a mixture of water and methyl isobutyl ketone (MIBK) at 0–5 °C, followed by acidification to ceftiofur hydrochloride. The terminal dosage form is a sterile oil suspension, requiring the bulk drug substance to undergo a terminal ethylene oxide sterilization validation per ISO 11135:2014 or aseptic crystallization in a grade B environment. Process-specific impurity indexing must additionally satisfy the requirement that ceftiofur-related desfuroylceftiofur conjugates be limited, and the dimer impurity is held at ≤ 1.0% by area normalization. Residual solvent analysis by headspace GC on the hydrochloride salt typically reports MIBK ≤ 500 ppm and ethyl acetate ≤ 5000 ppm. While the synthesis does not introduce elemental impurities beyond Class 2B catalysts, surveillance for nickel (leached from stainless steel reactors during prolonged acidic exposure) is maintained at ≤ 10 µg/g via ICP-OES. The compound operates under a FDA 21 CFR Part 211 veterinary drug GMP and is subject to batch certification in certain jurisdictions.

When Direct Condensation is Chosen Over Active Ester Method for Cefixime

The trihydrate form of cefixime, an oral third-generation cephalosporin, is accessed from Ethyl 2-Oximino-2-(2-Aminothiazole)-4-Acetate without isolation of a thioester intermediate; instead, the (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid obtained after methylation and hydrolysis is activated in situ with phosphorus oxychloride in dimethylacetamide (DMAc) and condensed directly with 7-amino-3-vinyl-3-cephem-4-carboxylic acid benzhydryl ester (7-AVNA benzhydryl ester). On a 4000 L reactor fitted with a reflux condenser and cryogenic jacket, a solution of the methoxyimino acid (1.0 eq) in DMAc is treated with phosphorus oxychloride (1.02 eq) at −20 °C to −15 °C to generate the mixed anhydride/DMF-adduct reactive species; after 45 minutes of aging, 7-AVNA benzhydryl ester (0.95 eq) dissolved in dichloromethane is introduced while maintaining the reaction mass at −25 °C to −20 °C. The charge ratio of the benzhydryl ester is kept on the deficit side to avoid unreacted cephalosporin nucleus that could co-elute with product during the subsequent crystallization. Following completion, the protecting benzhydryl ester group is removed with trifluoroacetic acid (3.5 volumes) in anisole scavenger at 20–25 °C over 2.5 h, and cefixime is precipitated as the trihydrate from aqueous methanol. Residual solvent testing per ICH Q3C for this route is particularly stringent for DMAc (Class 2, limit ≤ 1090 ppm), methanol (Class 2, ≤ 3000 ppm as per ICH but typically controlled to ≤ 1500 ppm for oral pediatric formulations), and anisole (Class 3, ≤ 5000 ppm). The potential formation of ethyl chloride during deprotection is monitored and kept at ≤ 300 ppm via headspace GC. Terminal product specifications align with USP 43 and EP 10.5 monographs for cefixime trihydrate: the (E)-isomer limit is ≤ 0.3%, and the sum of all other impurities is restricted to ≤ 0.8%. Because the direct condensation avoids thioester by-products such as 2-mercaptobenzothiazole, the impurity profile is substantially simplified, but precise stoichiometric control of phosphorus oxychloride is mandatory to avoid phosphate-related by-products that interfere with the final crystalline trihydrate morphology.